First-in-class Immunotherapy for Alzheimer’s Disease

Evinco Therapeutics offers exposure to a first-in-class immunotherapy addressing Alzheimer’s disease, one of the largest unmet needs in medicine, with the potential to expand into other neuroinflammatory conditions. 

Alzheimer’s disease is the most common cause of dementia which is now the leading cause of death in Australia. The Alzheimer’s disease therapeutics market is forecast to reach USD $17 billion by 2033 across the eight major markets driven by the ageing global population.

Non-Invasive Delivery Approach

Our NK cell-derived extracellular vesicles (EVs) are to be delivered intranasally, a non-invasive approach designed to directly access the brain and overcome key limitations of current therapies. Our program is supported by strong preclinical data and validated by a global pharmaceutical partnership guiding R&D toward proof-of-concept. Interest from a leading US VC group to assemble a funding consortium post-proof-of-concept further signals market confidence.

Strategic and Efficient Development Pathway

The development pathway is both strategic and efficient. We utilise a large animal (canine) model -Cognitive Dysfunction Syndrome (CDS) -which closely mirrors Alzheimer’s disease, generating clinically relevant behavioural and biomarker data.

Fast Path to Clinic

With animal safety and efficacy studies expected to conclude within two years, the program offers a fast path to the clinic. Melbourne-based neurologists are ready to initiate early clinician-sponsored trials, providing rapid access to human data.

Experienced Leadership and Global Potential

Backed by experienced leadership, including world-renowned stem cell pioneer, Prof. Alan Trounson AO, Evinco Therapeutics is positioned to deliver a transformative therapy with global reach and significant commercial upside.